Journals / Medicine Science / 2019 / Cilt: 8 - Sayı: 4

Evaluation of TNF alpha G308A promoter gene polymorphism and serum TNF alpha levels in patients with inflammatory bowel disease in Turkish population

Pages
1006–1010
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that TNF-α G308A gene polymorphism may be helpful in predicting the behavior of the disease in patients with ulcerative colitis but further studies are needed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tumor necrosis factor alpha (TNF-α) plays an important role in the pathophysiology of inflammatory bowel diseases (IBD).
📊
Key Findings & Data:In this study, we aimed to investigate the role of TNF-α G308A promoter gene polymorphisms and TNF-α level in patients with IBD and their associations with clinical features of the patients.
💡
Conclusion & Impact:These findings suggest that TNF-α G308A gene polymorphism may be helpful in predicting the behavior of the disease in patients with ulcerative colitis but further studies are needed
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Tumor necrosis factor alpha (TNF-α) plays an important role in the pathophysiology of inflammatory bowel diseases (IBD). In this study, we aimed to investigate the role of TNF-α G308A promoter gene polymorphisms and TNF-α level in patients with IBD and their associations with clinical features of the patients. This study included 91 patients with inflammatory bowel disease (46 patients with ulcerative colitis (UC) and 45 patients with Crohn’s disease (CD)) and 129 healthy controls (HC). Polymerase chain reaction and restriction fragment length polymorphism techniques were both used to explain the frequency of TNF-α polymorphisms and the relationship about clinical outcomes of patients with IBD. There was no statistically significant difference about genotype frequencies and serum TNF-α level between the three groups (UC, CD, HC) (all p>0.05). TNF-α G308A genes polymorphisms were compared in terms of disease localization, behaviour, activity, the use of anti TNF-α treatment and operative status in patients with CD and UC. Similarly, there was no statistically significant difference about genotype frequencies in terms of all these parameters in patients with CD (p> 0.05). However, In patient with UC, the frequency of A allele and AG genotype was significantly increased in moderate and severe UC cases (p= 0.004). These findings suggest that TNF-α G308A gene polymorphism may be helpful in predicting the behavior of the disease in patients with ulcerative colitis but further studies are needed

🔖

Cite This Article

KAHRAMAN, R., İPLİK, E. S., ÇAKMAKOĞLU, B. (2019). Evaluation of TNF alpha G308A promoter gene polymorphism and serum TNF alpha levels in patients with inflammatory bowel disease in Turkish population. Medicine Science, Cilt: 8 - Sayı: 4, 1006–1010. https://ajindex.com/articles/277597

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Frolkis A, Dieleman LA, Barkema HW, et al. Alberta IBD Consortium. Environment and the inflammatory bowel diseases. Can J Gastroenterol. 2013;27:18-24.
  2. Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis. 2004;10:300-11. Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis. 2011;17:1-5.
  3. Rodriguez-Bores L, Fonseca GC, Villeda MA, et al. Novel genetic markers in inflammatory bowel disease. World J Gastroenterol. 2007;13:5560-70.
  4. Dechairo B, Dimon C, Van Heel D, et al. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet. 2001;9:627-33.
  5. Muro M, López-Hernández R, Mrowiec A. Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region. World J Gastroenterol. 2014;20:15037-48.
  6. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297-30 D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology. 1999;116:1029-34.
  7. Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007;7:35-41
  8. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements:implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387-98. 11. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27:1743-50. 12. Wilson AG, de Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;177:557-60. 13. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3099. 14. González S, Rodrigo L, Martínez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn’s patients wit